# UCSF
## UC San Francisco Previously Published Works

**Title**

Potentiators of Defective ΔF508-CFTR Gating that Do Not Interfere with Corrector Action.

**Permalink**

https://escholarship.org/uc/item/242183mj

**Journal**

Molecular pharmacology, 88(4)

**ISSN**

0026-895X

**Authors**

Phuan, Puay-Wah
Veit, Guido
Tan, Joseph A
et al.

**Publication Date**

2015-10-01

**DOI**

10.1124/mol.115.099689

Peer reviewed

# Potentiators of Defective ΔF508–CFTR Gating that Do Not Interfere with Corrector Action [S]

Puay-Wah Phuan, Guido Veit, Joseph A. Tan, Walter E. Finkbeiner, Gergely L. Lukacs, and A. S. Verkman

*Departments of Medicine and Physiology (P.-W.P., J.A.T., A.S.V.) and Department of Pathology (W.E.F.), University of California, San Francisco, California; Department of Physiology and Groupe de Recherche Axé sur la Structure des Protéine (G.V., G.L.L.) and Department of Biochemistry (G.L.L.), McGill University, Montreal, Quebec, Canada*

## ABSTRACT

Combination drug therapies under development for cystic fibrosis caused by the ΔF508 mutation in cystic fibrosis transmembrane conductance regulator (CFTR) include a "corrector" to improve its cellular processing and a "potentiator" to improve its chloride channel function. Recently, it was reported that the approved potentiator N-(2,4-di-*tert*-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (Ivacaftor) reduces ΔF508-CFTR cellular stability and the efficacy of investigational correctors, including 3-(6-[([1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl) amino]-3-methyl-2-pyridinyl)-benzoic acid and 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-(1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1H-indol-5-yl), which might contribute to the modest reported efficacy of combination therapy in clinical trials. Here, we report the identification and characterization of potentiators that do not interfere with ΔF508-CFTR stability or corrector action. High-throughput screening and structure-activity analysis identified several classes of potentiators that do not impair corrector action, including tetrahydrobenzothiophenes, thiooxoaminothiazoles, and pyrazole-pyrrole-isoxazoles. The most potent compounds have an $EC_{50}$ for ΔF508-CFTR potentiation down to 18 nM and do not reduce corrector efficacy in heterologous ΔF508-CFTR–expressing cells or primary cultures of ΔF508/ΔF508 human bronchial epithelia. The ΔF508-CFTR potentiators also activated wild-type and G551D CFTR, albeit weakly. The efficacy of combination therapy for cystic fibrosis caused by the ΔF508 mutation may be improved by replacement of Ivacaftor with a potentiator that does not interfere with corrector action.

## Introduction

Mutations in the cAMP-activated chloride channel cystic fibrosis transmembrane conductance regulator (CFTR) cause the genetic disease cystic fibrosis (CF), in which defective epithelial fluid secretion and viscous mucus impairs the function of the lung, pancreas, and other organs. The most common CFTR mutation, ΔF508, is present in at least one allele in ~90% of CF patients in North America. The ΔF508 mutation causes CFTR misfolding, with retention at the endoplasmic reticulum, accelerated degradation, and impaired chloride channel function (Collins, 1992; Boucher, 2004; Davis, 2006; Riordan, 2008).

There has been great interest in the development of small-molecule, CFTR-targeted therapeutics to treat the underlying CFTR defect responsible for the clinical manifestations in CF (Ashlock and Olson, 2011; Hanrahan et al., 2013; Rowe and Verkman, 2013). N-(2,4-di-*tert*-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770; Ivacaftor) is approved for therapy of CF caused by mutations that affect CFTR gating but not cellular processing, including G551D and nine other point mutations (Ramsey et al., 2011; Davis et al., 2012; O'Reilly and Elphick, 2013). A combination drug approach has been adopted for therapy of CF caused by the ΔF508-CFTR mutation: a "corrector" to improve its cellular processing and a "potentiator" to improve its chloride channel function. Two reported phase 3 clinical trials of combination therapy of the investigational corrector 3-(6-[([1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl)amino]-3-methyl-2-pyridinyl)-benzoic acid (VX-809) with VX-770 showed modest clinical benefit in ΔF508 homozygous CF patients, with a range of 2.6–4% improvement in lung function as measured by forced expiratory volume in 1 second (NCT01807949; NCT01807923; Boyle et al., 2014; Vertex Pharmaceuticals press release, Cambridge, MA). Two recent papers reported that VX-770

ABBREVIATIONS: CF, cystic fibrosis; CFBE, CFBE41o⁻ TetON; FRT, Fisher rat thyroid; HA, human influenza hemagglutinin; HRP, horseradish peroxidase; PBS, phosphate-buffered saline; VX-661, 1-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-(1-[(2R)-2,3-dihydroxypropyl]-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1H-indol-5-yl); VX-770, N-(2,4-di-*tert*-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide; VX-809, 3-(6-[([1-(2,2-difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl)amino]-3-methyl-2-pyridinyl)-benzoic acid; YFP, yellow fluorescence protein.

reduces ΔF508-CFTR cellular stability and the efficacy of VX-809 and a second investigational corrector, 1-(2,2-difluoro-1, 3-benzodioxol-5-yl)-*N*-(1-[(2*R*)-2,3-dihydroxypropyl]-6-fluoro-2-(2-hydroxy-1,1-dimethylethyl)-1*H*-indol-5-yl) (VX-661) (Cholon et al., 2014; Veit et al., 2014). The reduced corrector efficacy in cells chronically exposed to VX-770 results from impaired ΔF508-CFTR folding efficiency at the endoplasmic reticulum and accelerated plasma membrane turnover (Veit et al., 2014), which might account, in part, for the modest clinical efficacy of combination therapy.

We reasoned that a potentiator that does not reduce ΔF508-CFTR stability and corrector efficacy may be superior to VX-770 for combination therapy. The study here was done to identify potentiators that do not impair corrector action. This project was motivated by the observation that some potentiators, such as P5, do not destabilize ΔF508-CFTR or reduce corrector efficacy (Veit et al., 2014). The tetrahydrobenzothiophene P5 was the first reported CFTR potentiator, as identified by our laboratory using a cell-based functional high-throughput screen (Yang et al., 2003). Here, we screened 273 analogs of P5 as well as 60,000 unrelated drug-like synthetic small molecules to identify potentiators that do not interfere with corrector action. Nanomolar-potency potentiators were identified and characterized, which do not interfere with corrector action or impair ΔF508-CFTR cellular stability.

## Materials and Methods

**Cell Lines.** Fisher rat thyroid (FRT) epithelial cells stably expressing ΔF508, wild-type, or G551D CFTR, together with halide-sensitive green fluorescent protein yellow fluorescence protein (YFP)–H148Q/I152L/F46L (Galietta et al., 2001) were as reported (Ma et al., 2002; Pedemonte et al., 2005). FRT cells were cultured in Coon's modified Ham's F12 medium, supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and 100 $\mu$g/ml streptomycin. For primary screening, FRT cells expressing ΔF508-CFTR were plated at 50,000 cells/well 18–24 hours prior to screening.

CFBE41o⁻ TetON (CFBE) cells expressing ΔF508-CFTR–horseradish peroxidase (HRP) or ΔF508-CFTR-3HA were as described (Veit et al., 2012, 2014). CFBE cells were grown in minimal essential medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, and 10 mM HEPES. For propagation, cells were cultured in plastic flasks coated with 10 $\mu$g/ml human fibronectin, 30 $\mu$g/ml calf-skin collagen, and 100 $\mu$g/ml bovine serum albumin diluted in LHC-8 basal medium (Invitrogen). For chemiluminescence assay, CFBE cells were plated in black, 96-well microplates (Costar, Corning Inc., Lowell, MA) at 15,000 cells/well. ΔF508-CFTR-HRP expression was induced 24 hours after plating with 0.5 $\mu$g/ml doxycycline for 2 days before assay.

**Primary Cultures of ΔF508/ΔF508 Human Bronchial Epithelial Cells.** Primary human ΔF508/ΔF508 CF bronchial epithelial cells were isolated and then cultured on semipermeable inserts (Snapwell, Corning Inc.) in ALI media at an air-liquid interface, as described (Yamaya et al., 1992; Fulcher and Randell, 2013). Media was changed every 2–3 days. All protocols involving the collection and use of human tissues and cells were reviewed and approved by the University of California, San Francisco Institutional Review Board.

**Compounds.** Sixty thousand chemically diverse, drug-like synthetic compounds (>90% with a molecular size of 250–500 Da; ChemDiv Inc., San Diego, CA) were used for primary screening. For optimization, 387 commercially available analogs of two chemical classes were tested as well as 273 analogs of P5. Analogs of active compounds (purity > 95%) were purchased from ChemDiv Inc.

**Screening Procedures.** For the assay of potentiator activity, FRT cells expressing ΔF508-CFTR and YFP were grown at 37°C/5%

CO₂ for 18–24 hours and then for 18–24 hours at 27°C, as described (Yang et al., 2003). At the time of the assay, cells were washed with phosphate-buffered saline (PBS) and then incubated for 10 minutes with PBS (60 $\mu$l) containing forskolin (20 $\mu$M) and the test compound (2.5 $\mu$M final concentration). Each well was assayed individually for iodide influx by recording fluorescence continuously (200 milliseconds per point) for 2 seconds (baseline) and then for 12 seconds after rapid addition of 180 $\mu$l PBS, in which 137 mM chloride was replaced by iodide. Fluorescence was recorded using a TECAN Infinite M1000 plate reader (TECAN Groups Ltd., Mannedorf, Switzerland), equipped with an automated stacker and dual syringe pumps (excitation: 500 ± 10 nm; emission: 535 ± 10 nm). The initial iodide influx rate was computed as described (Ma et al., 2002). All compound plates contained negative controls (dimethylsulfoxide vehicle) and positive controls (50 $\mu$M genistein).

**Chemiluminescence Assays.** CFBE cells expressing ΔF508-CFTR-HRP were incubated with 100 $\mu$l of medium containing the test compound, 3 $\mu$M VX-809, and 0.5 $\mu$g/ml doxycycline for 24 hours at 37°C. All plates contained negative controls (dimethylsulfoxide vehicle) and positive controls (3 $\mu$M VX-809). Cells were washed 4 times with PBS, and HRP activity was assayed by the addition of 50 $\mu$l/well of the HRP substrate (WesternBright Sirius Kit; Advansta Corp., Menlo Park, CA), as described (Phuan et al., 2014). After shaking for 5 minutes, chemiluminescence was measured using a TECAN Infinite M1000 plate reader (integration time of 100 milliseconds).

**Short-Circuit Current Measurements.** Short-circuit current measurements were done as previously described (Phuan et al., 2014). FRT cells expressing ΔF508, wild-type, or G551D CFTR were cultured on inserts (Snapwell, Corning) for 5–7 days and used when the transepithelial resistance was >2000 $\mu\Omega$/cm². For potentiator testing, the ΔF508-CFTR–expressing FRT cells were incubated for 18–24 hours at 27°C before measurements. The basolateral solution contained 120 mM NaCl, 3 mM KCl, 1 mM CaCl₂, 1 mM MgCl₂, 10 mM glucose, 25 mM NaHCO₃, and 5 mM HEPES, pH 7.4. In the apical bathing solution, 60 mM NaCl was replaced by Na gluconate and CaCl₂ was increased to 2 mM. Solutions were bubbled with 95% O₂/5% CO₂ and maintained at 37°C. The basolateral membrane was permeabilized with 250 $\mu$g/ml amphotericin B. Primary cultures of human bronchial epithelial cells were measured after 21–28 days of culture when cells reached full differentiation, and the transepithelial resistance was >1000 $\mu\Omega$/cm². The primary cultures were incubated with VX-809 (10 $\mu$M) at the basolateral side for 18–24 hours at 37°C prior to measurements. The apical and basolateral chambers contained identical solutions: 130 mM NaCl, 0.38 mM KH₂PO₄, 2.1 mM K₂HPO₄, 1 mM MgCl₂, 1 mM CaCl₂, 25 mM NaHCO₃, and 10 mM glucose. Solutions were bubbled with 5% CO₂/95% O₂ and maintained at 37°C. Hemichambers were connected to a DVC-1000 voltage clamp (World Precision Instruments Inc., Sarasota, FL) via Ag/AgCl electrodes and 1 M KCl agar bridges for recording of the short-circuit current.

**CFTR Plasma Membrane Density Measurements.** The plasma membrane density of triple human influenza hemagglutinin (3HA)–tagged CFTR was determined by cell surface enzyme-linked immunosorbent assay, as described (Okiyoneda et al., 2010). Plasma membrane density measurements were normalized to cell viability determined by Alamar Blue assay (Invitrogen).

**Immunoblotting.** Immunoblotting was performed as described (Okiyoneda et al., 2010). The 3HA-tagged ΔF508-CFTR was detected by monoclonal mouse anti-HA antibody (MMS101R; Covance, Princeton, NJ), and monoclonal mouse anti–Na⁺/K⁺-ATPase antibody (H3; Santa Cruz Biotechnology, Santa Cruz, CA) was used to confirm equal loading.

## Results

**Screening Strategy.** Figure 1, A and B, diagrams the assays used to identify potentiators that do not interfere with ΔF508-CFTR corrector action. The primary high-throughput screen for potentiators was done using FRT cells stably

expressing human ΔF508-CFTR and an iodide-sensitive YFP. The cells were cultured for 24 hours at 27°C to target ΔF508-CFTR to the plasma membrane (low-temperature rescue). Iodide influx was measured by extracellular addition of iodide in the presence test compound (at 2.5 $\mu$M) and cAMP agonist (20 $\mu$M forskolin). Active potentiators identified in the primary screen were counter-screened for the effect on the corrector action using a human lung epithelium–derived (CFBE41o⁻) cell line (Ehrhardt et al., 2006) stably transfected with human ΔF508-CFTR containing an HRP inserted in its fourth extracellular loop (Phuan et al., 2014; Veit et al., 2014). The expression of wild-type CFTR in CFBE is under the control of the same expression vector as in the ΔF508-3HA and ΔF508-HRP cells reported previously (Veit et al., 2012), in which CFTR expression was shown to be similar to endogenous levels in Calu-3 cells. The ΔF508-HRP CFBE cells were cultured on 96-well plates and then potentiators (10 $\mu$M) were added for 18–24 hours together with VX-809 (3 $\mu$M). Cell surface ΔF508-CFTR was quantified by a luminescence readout. Potentiators that interfere with ΔF508-CFTR cellular stability or corrector action reduce the luminescence signal. Figure 1C shows the reduced VX-809 corrector efficacy in cells following chronic exposure to VX-770 or genistein, but not P5, as reported before (Veit et al., 2014). Chemical structures are shown in Fig. 1D.

**ΔF508-CFTR Potentiators Identified from Screens.** Sixty thousand drug-like, synthetic small molecules were screened for potentiator activity as well as 273 analogs of

tetrahydrobenzothiophene P5. As summarized in Fig. 2A, 230 active compounds were identified from the 60,000-molecule screen and 38 active P5 analogs, with activity defined as >50% of the maximal iodide influx produced by forskolin (20 $\mu$M) + genistein (50 $\mu$M). The 50 most active compounds were counter-screened for effect on corrector efficacy in VX-809–treated ΔF508-HRP CFBE cells, which produced 41 compounds from the 60,000-molecule screen and 10 P5 analogs that did not significantly reduce the luminescence signal. We choose the 12 most active compounds and grouped them into nine compound classes (Fig. 2B). Among the active compounds was a thiophene (compound G01) with structural similarity to tetrahydrobenzothiophene P5. In addition, structurally similar compounds included two 2-thioxo-4-amino-thiazoles (compounds A01 and A02) and three pyrazole-pyrrole isoxazoles (compounds H01, H02, and H03). Supplemental Table 1 summarizes the concentration-dependence data for selected compounds in ΔF508-CFTR FRT cells, with the most potent compounds showing an EC$_{50}$ of ~0.03 $\mu$M for ΔF508-CFTR potentiation, without interference with VX-809 corrector action and with potentiator efficacy similar to maximal genistein.

**Structure-Activity Analysis.** Based on potency data, compounds of classes A, H, and P5 were selected for further study. One hundred and eighty-nine commercially available class A and class H analogs were tested. Figure 3A shows the concentration-dependence data of selected compounds in



**Fig. 1.** Screens for identification of ΔF508-CFTR potentiators that do not interfere with corrector action. (A) Potentiator screen using FRT cells coexpressing ΔF508-CFTR and YFP iodide–sensing protein. Cells were incubated at 27°C for 24 hours before assay to target ΔF508-CFTR to the plasma membrane. Test compounds at 2.5 $\mu$M were added for 10 minutes at room temperature in the presence of forskolin (20 $\mu$M) before iodide addition. (B) Cell-surface expression screen using ΔF508-CFTR-HRP CFBE cells. Cells were incubated with test compounds and 3 $\mu$M VX-809 for 24 hours at 37°C. Cell-surface ΔF508-CFTR was assayed by a luminescence readout of HRP activity. (C) Luminescence readout of cell surface ΔF508-CFTR after 24-hour incubation with potentiators VX-770, P5, or genistein, together with 3 $\mu$M VX-809 (S.E.; $n$ = 4). (D) Chemical structures of potentiators.

**A**

FRT ΔF508-CFTR
primary screen
60,000 compounds

↓

230 hits (>50 % maximal
of genistein + forskolin)

↓

50 hits (tested with
CFBE-ΔF508-CFTR-HRP
assay)

↓

9 compound classes

FRT ΔF508-CFTR
463 P5 analogs

↓

38 hits (>50 % maximal
of genistein + forskolin)

↓

10 hits (tested with
CFBE-ΔF508-CFTR-HRP
assay)

**B**



A-01    A-02    B-01    C-01

D-01    E-01    F-01    G-01

H-01    H-02    H-03    I-01

**Fig. 2.** Screening results. (A) Summary of screening results. (B) Chemical structures of nine classes of potentiators identified from the screen.

ΔF508-CFTR FRT cells. Figure 3B shows that these compounds do not significantly impair VX-809 corrector action in ΔF508-HRP CFBE cells. Supplemental Tables 2–4 summarize the $EC_{50}$ values for selective active compounds. Several class A analogs, including A03, A04, and A05, have a similar or better $EC_{50}$ than compounds A01 and A02 identified in the primary screen. The most active compound, A04, has an $EC_{50}$ of ~18 nM. For class H, only a few analogs showed an $EC_{50}$ similar to that of the original compounds H01 and H02. Several P5 analogs were more potent than P5, including P11 and P12.

Structural determinants of activity for class A, H, and P5 compounds are summarized in Fig. 3C. Correctors of class A, 2-thioxo-4-aminothiazoles, with the best activity have $R^1$ substituents of benzyl and 2-methyl-furan (Supplemental Table 1; A03 and A08). Reduced activity was seen with $R^1$ as halide-substituted benzene, alkyl-substituted benzene, methyl, ethyl, phenethylene, and allyl moieties. Interestingly, a wide array of substituents, including piperdine, pyrrolidine, and substituted anilines, were tolerated at $R^2$, with the most active being $R^2$ as a simple ester (A04) and benzylamine (A03 and A05). Other rings, such as azepane, benzylpyridine, and morpholine, reduced activity. Class H compounds contain three linked heterocycles: pyrazole-pyrrole-isoxazole. Analogs containing only two rings, such as pyrrole-isoxazole and pyrazole-isoxazole, were inactive, indicating that all three heterocycles are needed for activity. Limited substituents on the isoxazole were studied, with small substituents, such as ethyl and methyl giving better activity, whereas bulky groups, such as isopropyl, giving reduced activity. The position at which the isoxazole linkage to pyrrole is crucial, as changing from the 3 to 2 position abolished activity. Changing the linker between the pyrazole and pyrrole rings from methylene (X:$CH_2$) to carbonyl (X:C=O) resulted in loss of activity. The substitution ($R^2$) on the pyrazole affected activity, with electron-poor rings, such as 4-fluorobenzene (H04) and 3-bromobenzene (H05), giving the best activity, whereas electron-neutral (H06) or electronic-rich (H10) rings giving reduced activity.

The benzothiophene P5, which contains a six-membered ring ($n = 1$), had greater potentiator activity than analogs with a five-membered ring ($n = 0$) (P18) or a seven-membered ring ($n = 2$). At the $R^1$ position, the primary carboxamide ($CONH_2$)

is crucial for activity, as replacing $R^1$ with cyano, ester, methyl-ketone, substituted anilines as well as substitutions on carboxamides resulted in loss of activity. Similarly, substitution on the 2 position ($R^2$) of the tetrahydrobenzo ring with methyl and $t$-butyl also resulted in loss of activity. Alterations of $R^3$ gave more potent P5 analogs, including replacement of the 2-chlorobenzene in P5 by 2-fluorobenzene (P12) or 2-thiophene (P11). Close structural analogs of P5 with chloro, methoxy, and nitro groups substituted at different positions showed a similar or better $EC_{50}$ than P5. Changing $R^3$ from benzene to other substituted benzyl, biphenyl, and phenoxy-phenyls reduced activity.

**Biochemical Studies of Potentiator Effect on ΔF508-CFTR Expression.** To biochemically confirm that chronic potentiator exposure does not interfere with ΔF508-CFTR plasma membrane expression, we used CFBE41o⁻ cells stably expressing the 3HA-tagged ΔF508-CFTR (Sharma et al., 2004). 3HA-ΔF508-CFTR CFBE cells were treated with VX-770 and potentiators for 24 hours. Figure 4A (left) showed that while VX-770 reduced ΔF508-CFTR plasma membrane expression, most of the potentiators did not affect ΔF508-CFTR expression, with the exception of compounds H01 and H02. When the potentiators were incubated together with VX-809 (Fig. 4A, center) or VX-661 (Fig. 4A, right), most potentiators did not reduce ΔF508-CFTR PM expression. Compounds H01 and H02 reduced ΔF508-CFTR plasma membrane expression, although not as much as VX-770.

Potentiator effects on ΔF508-CFTR cellular expression were examined by immunoblot analysis. Potentiators were incubated alone or with 3 $\mu$M VX-809 or 3 $\mu$M VX-661 in rΔF508-3HA-CFBE cells for 48 hours at 26°C before lysis and immunoblot analysis (Fig. 4B). Densitometric analyses were done to quantify complex glycosylated ΔF508-CFTR (C-band) in cell lysates (Fig. 4C). Most of the potentiators did not significantly decrease the amount of the complex glycosylated ΔF508-CFTR (C-band), alone or in combination with VX-809 or VX-661. Several class H compounds (H01, H02, and H03) reduced the amount of the complex glycosylated ΔF508-CFTR, similar to data in Fig. 4A. Two P5 analogs, P15 and P17, appeared to decrease complex glycosylated ΔF508-CFTR in VX-661, but not VX-809 treated cells, suggesting that potentiator interference of corrector action might be corrector dependent.

**Fig. 3.** Structure-activity relationships of class A, H, and P5 potentiators. (A) Concentration-dependence data of class A, H, and P5 analogs in ΔF508-CFTR FRT cells (S.E.; $n = 3$). (B) Cell-surface ΔF508-CFTR expression in CFBE cells following incubation with 10 $\mu$M class A or H compounds or 2 $\mu$M P5 analogs, together with 3 $\mu$M VX-809 (S.E.; $n = 4$). A 100% luminescence signal is defined as the background-subtracted luminescence signal of VX-809–corrected ΔF508-HRP CFBE cells. (C) Structural determinants of potentiator activity of class A, H, and P5 compounds.

**Short-Circuit Measurements in Transfected FRT Cells and in Primary Cultures of ΔF508/ΔF508 Human Bronchial Epithelial Cells.** Based on the results of the biochemical and structure-activity relationship studies, we chose the most potent class A and P5 analogs, A04 and P12, for further characterization by short-circuit current measurements. Apical membrane chloride current was measured in ΔF508-CFTR–expressing FRT cells after low-temperature rescue in response to A04 and P12, with data for VX-770 shown for comparison. Figure 5A shows the concentration-dependent increases in the apical membrane current seen in the presence of forskolin. Genistein produced a minimal increase in the chloride current after maximal A04, P12, and VX-770. CFTR$_{inh}$-172 abolished all of the chloride current. As measured by a short-circuit current, the apparent EC$_{50}$ for A04 and P12 potentiator activity was ~100 nM. The EC$_{50}$ for VX-770 was ~30 nM, in agreement with published data (Van Goor et al., 2009). In side-by-side short-circuit current recordings (unpublished data), maximal potentiator concentrations produced open probabilities of ~0.37 and ~0.34 for A04 and P12, respectively, as referenced against the open probability of ~0.40 produced by maximal VX-770 (Van Goor et al., 2009). A04 and P12 were also tested in FRT cells expressing wild-type CFTR (Fig. 5B). A low concentration of

forskolin (0.5 $\mu$M) was used to prevent full activation of wild-type CFTR, which would mask potentiator action. After potentiator additions, 10 $\mu$M forskolin was added to fully activate wild-type CFTR, followed by 50 $\mu$M genistein, which had little effect, followed by 10 $\mu$M CFTR$_{inh}$-172, which inhibited all of the chloride current. A04-activated wild-type CFTR when added after 0.5 $\mu$M forskolin, whereas P12 showed partial activation, with an apparent EC$_{50}$ of ~200 nM for both compounds. A04 and P12 were also tested in FRT cells expressing G551D-CFTR (Fig. 5C). G551D-CFTR produced little chloride current with maximal forskolin. A04 partially activated G551D-CFTR but only at a high concentration (10 $\mu$M), whereas P12 showed minimal activation even at a high concentration.

Short-circuit current measurements were also done in well differentiated primary cultures of human bronchial epithelial cells from a ΔF508-homozygous subject. A short-circuit current was measured after chronic (18–24 hours) treatment with A04 or P12 together with VX-809. Cells incubated with 3 $\mu$M VX-809 alone showed an increased short-circuit current in response to forskolin and VX-770, which was inhibited by CFTR$_{inh}$-172 (Fig. 6A, left). Little current was seen in the absence of VX-809. Cotreatment with 5 $\mu$M A04 or P12 together with 3 $\mu$M VX-809 did not reduce the chloride current

**Fig. 4.** Potentiator effects on ΔF508-CFTR plasma membrane expression. (A) Plasma membrane expression of low-temperature rescued (26°C, 48 hours followed by 1-hour chase at 37°C) ΔF508-CFTR-3HA (rΔF508-3HA) in CFBE. Cells were treated with the indicated potentiators for 24 hours (P11–17, A1–2, and A4, 1 μM; H1–3, C1, D1, E1, and F1, 5 μM) alone (left) or in the presence of 3 μM VX-809 (center) or 3 μM VX-661 (right). Data are expressed as the percentage of dimethylsulfoxide-treated controls (S.E.; $n = 3$). (B) Representative immunoblots and (C) quantification of the potentiator effect on the expression pattern of rΔF508-3HA (26°C; 48 hours) in CFBE cells. Cells were treated with the indicated potentiators alone or in combination with 3 μM VX-809 or 3 μM VX-661 for 24 hours at 26°C. CFTR was visualized with anti-HA antibody, anti–Na⁺/K⁺-ATPase antibody served as the loading control. Densitometric analysis of complex-glycosylated (band C, empty arrowhead) ΔF508-CFTR is expressed as the percentage of dimethylsulfoxide control (S.E.; $n = 3–9$).

when compared with VX-809 alone (Fig. 6A, center and right). Figure 6B summarizes the chloride current responses from the data, as in Fig. 6A, indicating that chronic treatment with A04 and P12 did not interfere with VX-809 corrector action. Finally, the potentiator action of A04 and P12 was tested in the primary cultures of ΔF508/ΔF508 human bronchial epithelial cells after VX-809 correction. Figure 6C shows the A04 and P12 concentration-dependent increases in the chloride current in the presence of forskolin. Genistein produced a minimal increase in the chloride current after maximal A04

or P12, and 10 μM CFTR$_{inh}$-172 abolished all of the chloride current. The apparent EC$_{50}$ for A04 and P12 potentiator activity was <300 nM in the ΔF508/ΔF508 human bronchial epithelial cells.

## Discussion

This study was done to identify new potentiators that do not interfere with the action of ΔF508-CFTR correctors. This study was motivated by recent studies showing that 1) the

**Fig. 5.** Functional assays in FRT cells expressing ΔF508, wild-type, and G551D CFTR. Representative short-circuit current measured in FRT cells expressing ΔF508-CFTR (A), wild-type CFTR (B), and G551D-CFTR (C) showing responses to indicated concentrations of forskolin (fsk), A04, P12, and VX-770. The ΔF508-CFTR–expressing cells were incubated at 27°C for 24 hours before measurement. Genistein (gen, 50 $\mu$M) and CFTR$_{inh}$-172 (10 $\mu$M) were added where indicated.

approved potentiator Ivacaftor (Kalydeco) reduced the correction efficacy of VX-809 and VX-661 (Cholon et al., 2014; Veit et al., 2014); 2) some, but not all, potentiators reduce correction efficacy (Veit et al., 2014); and 3) combination VX-770/VX-809 therapy showed limited clinical efficacy (Boyle et al., 2014; Vertex Pharmaceuticals press release, Cambridge, MA). VX-770 has been approved to treat CF patients with defective CFTR gating but not cellular processing, including G551D-CFTR. However, the majority of CF patients carry the ΔF508 mutation, in which the protein has defective gating as well as trafficking to the cell membrane. The limited clinical efficacy of combination VX-809/VX-770 therapy could perhaps be explained by in vitro data (Cholon et al., 2014; Veit et al., 2014), showing that VX-770 reduces the correction efficacy of VX-809 and VX-661 by increasing the turnover rate and destabilizing corrected ΔF508-CFTR. Thus, potentiators that do not interfere with corrector action or impair CFTR stability/turnover rate could have an improved clinical benefit over VX-770 in combination therapy of CF caused by the ΔF508 mutation and potentially other mutations.

Our strategy to identify ΔF508-CFTR potentiators that do not interfere with the corrector action used an initial, high-throughput functional, cell-based screen involving assay of iodide influx. Active compounds identified from the initial screen were counter-screened using a human lung epithelium-derived cell line expressing transfected HRP-tagged ΔF508-CFTR. The HRP-tag was engineered in the fourth extracellular loop for robust plate reader–based luminescence measurements of cell surface CFTR expression. A large number and variety of potentiators were identified, many of which did not interfere with corrector action. The most active potentiators, A04 and P12, were found to have nanomolar potency, as shown by short-circuit current measurements in low-temperature rescued ΔF508-CFTR FRT cells and VX-809–treated ΔF508/ΔF08 human bronchial epithelial cells. Interestingly, P12 and A04 only minimally activated G551D-CFTR at high concentrations. Computational modeling has suggested that increased stability of G551D-CFTR compared with wild-type CFTR renders the G551D-CFTR protein too rigid and inflexible for channel gating (Serohijos et al., 2008). VX-770–mediated destabilization of G551D-CFTR might increase

**Fig. 6.** Functional assays in primary cultures of human bronchial epithelial cells from a homozygous ΔF508 CF patient. (A) Cultures were incubated at 37°C for 24 hours with 3 μM VX-809 (gray curve shows dimethylsulfoxide-vehicle treated cells) (left), 3 μM VX-809 + 5 μM A04 (center), or 3 μM VX-809 + 5 μM P12 (right). Amiloride (10 μM), VX-770 (10 μM), forskolin (fsk; 20 μM), and CFTR$_{inh}$-172 (10 μM) were added where indicated. (B) Summary of changes in short-circuit current ($\Delta I_{sc}$) from experiments as in (A) (S.E.; $n$ = 3 cultures each). (C) Short-circuit current measured in the ΔF508/ΔF508 human bronchial epithelial cells showing responses to indicated A04 and P12 concentrations. Cells were incubated at 37°C for 24 hours with 3 μM VX-809 before measurement. Genistein (gen; 50 μM) and CFTR$_{inh}$-172 (10 μM) were added where indicated.

G551D-CFTR flexibility and result in restored channel gating function (Cholon et al., 2014). Our results with P12 and A04 suggest that these classes of compound potentiate CFTR gating most likely by a different mechanism of action from VX-770.

In addition to the functional and cell surface enzyme-linked immunosorbent assay measurements of potentiator effect on corrector efficacy, which included studies on primary cultures of ΔF508/ΔF508 human bronchial cells, biochemical analyses were done to quantify total cellular ΔF508-CFTR and the accumulation of complex-glycosylated ΔF508-CFTR. Most compounds identified from the screen did not reduce the level of complex glycosylated ΔF508-CFTR, except several class H compounds, which might preclude this class of compounds for further development. As noted, an interesting observation is that P16 and P17 appeared to decrease complex-glycosylated ΔF508-CFTR in VX-661, but not VX-809 or control cells. Potentiator interference of the corrector action thus might be corrector dependent. A specific potentiator-corrector combination might produce a different therapeutic effect in different CFTR mutations. Thorough in vitro studies of potentiator-corrector combinations using pertinent CF mutations might be crucial before clinical trials. The modular multiassay approach adopted in this study could facilitate the selection of potentiators for drug development.

Some 2-thioxo-4-aminothiazoles (class A) have reported antifungal (Chhabria et al., 2011) and antitubercular (Chhabria et al., 2014) activity. Reported biologic activities for tetrahydrobenzothiophenes include inhibition of tyrosine kinase receptor FLT3 (Patch et al., 2006) and influenza virus RNA polymerase assembly (Massari et al., 2013). Both thioxoaminothiazoles and tetrahydrobenzothiophenes can be prepared in three to five steps from commercially available starting materials, thus allowing facile and rapid diversification of these scaffolds for further medicinal chemistry and structure-activity

relationship efforts to improve biologic activities and pharmacological properties. There are no biologic reports on the exact pyrazole-pyrrole-isoxazole ring system, as found in class H compounds. However, some pyrazoles with moderate structural similarity to class H have been reported to be 5-HT2A/5-HT2C receptor antagonists (Schadt et al., 2004), p38 kinase inhibitors (Naraian et al., 2005), and androgen receptor antagonists (Ito et al., 2009). To our knowledge, the channel-modulating effects of class A and H compounds have not been reported.

In summary, the results here provide a proof of concept for the identification of nanomolar-potency potentiators that do not interfere with the corrector action or CFTR stability.

### Authorship Contributions

*Participated in research design:* Phuan, Veit, Lukacs, Verkman.
*Conducted experiments:* Phuan, Veit, Tan.
*Wrote or contributed to the writing of the manuscript:* Phuan, Veit, Finkbeiner, Lukacs, Verkman.

### References

Ashlock MA and Olson ER (2011) Therapeutics development for cystic fibrosis: a successful model for a multisystem genetic disease. *Annu Rev Med* **62**:107–125.

Boucher RC (2004) New concepts of the pathogenesis of cystic fibrosis lung disease. *Eur Respir J* **23**:146–158.

Boyle MP, Bell SC, Konstan MW, McColley SA, Rowe SM, Rietschel E, Huang X, Waltz D, Patel NR, and Rodman D; VX09-809-102 study group (2014) A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial. *Lancet Respir Med* **2**:527–538.

Chhabria M, Patel S, Dholakia S, Mistry H, and Patel S (2014) Synthesis and antitubercular activity of a series of thiazole derivatives. *Anti-Infective Agents* **12**: 149–158.

Chhabria M, Rathod I, Vala K, and Patel P (2011) Identification of important structural features of thiazolo[4,5-d]pyrimidines required for potent antifungal activity. *Med Chem Res* **20**:1450–1454.

Cholon DM, Quinney NL, Fulcher ML, Esther CR, Jr, Das J, Dokholyan NV, Randell SH, Boucher RC, and Gentzsch M (2014) Potentiator ivacaftor abrogates pharmacological correction of ΔF508 CFTR in cystic fibrosis. *Sci Transl Med* **6**:246ra96.

Collins FS (1992) Cystic fibrosis: molecular biology and therapeutic implications. *Science* **256**:774–779.

Davis PB (2006) Cystic fibrosis since 1938. *Am J Respir Crit Care Med* **173**:475–482.

Davis PB, Yasothan U, and Kirkpatrick P (2012) Ivacaftor. *Nat Rev Drug Discov* **11**: 349–350.

Ehrhardt C, Collnot EM, Baldes C, Becker U, Laue M, Kim KJ, and Lehr CM (2006) Towards an in vitro model of cystic fibrosis small airway epithelium: characterisation of the human bronchial epithelial cell line CFBE41o-. *Cell Tissue Res* **323**: 405–415.

Fulcher ML and Randell SH (2013) Human nasal and tracheo-bronchial respiratory epithelial cell culture. *Methods Mol Biol* **945**:109–121.

Galietta LJ, Haggie PM, and Verkman AS (2001) Green fluorescent protein-based halide indicators with improved chloride and iodide affinities. *FEBS Lett* **499**: 220–224.

Hanrahan JW, Sampson HM, and Thomas DY (2013) Novel pharmacological strategies to treat cystic fibrosis. *Trends Pharmacol Sci* **34**:119–125.

Ito M, Suzaki T, Yamamoto S (2009) inventors, Ito M, Suzaki T, Takeda Pharmaceutical, Yamamoto S, assignee. Substituted pyrazole derivative. Patent WO2009028543 A1. 2009 Mar 5.

Ma T, Vetrivel L, Yang H, Pedemonte N, Zegarra-Moran O, Galietta LJ, and Verkman AS (2002) High-affinity activators of cystic fibrosis transmembrane conductance regulator (CFTR) chloride conductance identified by high-throughput screening. *J Biol Chem* **277**:37235–37241.

Massari S, Nannetti G, Goracci L, Sancineto L, Muratore G, Sabatini S, Manfroni G, Mercorelli B, Cecchetti V, and Facchini M et al. (2013) Structural investigation of cycloheptathiophene-3-carboxamide derivatives targeting influenza virus polymerase assembly. *J Med Chem* **56**:10118–10131.

Naraian AS, et al. (2005) inventors, Pharmacia Corporation, assignee. Substituted pyrazoles as p38 kinase inhibitors. U.S. patent 6979686 B1. 2005 Dec 27.

Okiyoneda T, Barrière H, Bagdány M, Rabeh WM, Du K, Höhfeld J, Young JC, and Lukacs GL (2010) Peripheral protein quality control removes unfolded CFTR from the plasma membrane. *Science* **329**:805–810.

O'Reilly R and Elphick HE (2013) Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis. *Drug Des Devel Ther* **7**:929–937.

Rowe SM and Verkman AS (2013) Cystic fibrosis transmembrane regulator correctors and potentiators. *Cold Spring Harb Perspect Med* **3**:a009761.

Patch RJ, Baumann CA, Liu J, Gibbs AC, Ott H, Lattanze J, and Player MR (2006) Identification of 2-acylaminothiophene-3-carboxamides as potent inhibitors of FLT3. *Bioorg Med Chem Lett* **16**:3282–3286.

Pedemonte N, Sonawane ND, Taddei A, Hu J, Zegarra-Moran O, Suen YF, Robins LI, Dicus CW, Willenbring D, and Nantz MH et al. (2005) Phenylglycine and sulfonamide correctors of defective delta F508 and G551D cystic fibrosis transmembrane conductance regulator chloride-channel gating. *Mol Pharmacol* **67**:1797–1807.

Phuan PW, Veit G, Tan J, Roldan A, Finkbeiner WE, Lukacs GL, and Verkman AS (2014) Synergy-based small-molecule screen using a human lung epithelial cell line yields ΔF508-CFTR correctors that augment VX-809 maximal efficacy. *Mol Pharmacol* **86**:42–51.

Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Dřevínek P, Griese M, McKone EF, Wainwright CE, and Konstan MW et al.; VX08-770-102 Study Group (2011) A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. *N Engl J Med* **365**:1663–1672.

Riordan JR (2008) CFTR function and prospects for therapy. *Annu Rev Biochem* **77**: 701–726.

van Amsterdam C, Arlt M, Bartoszyk G, Finsinger D, Schadt O, Schiemann K, Seyfried C (2004) inventors, Merck Patent Gmbh, assignee. Substituierte Pyrazolverbindungen. Patent DE10315569 A1. 2004 Oct 14.

Serohijos AW, Hegedus T, Aleksandrov AA, He L, Cui L, Dokholyan NV, and Riordan JR (2008) Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function. *Proc Natl Acad Sci USA* **105**:3256–3261.

Sharma M, Pampinella F, Nemes C, Benharouga M, So J, Du K, Bache KG, Papsin B, Zerangue N, and Stenmark H et al. (2004) Misfolding diverts CFTR from recycling to degradation: quality control at early endosomes. *J Cell Biol* **164**:923–933.

Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, and Hazlewood A et al. (2009) Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. *Proc Natl Acad Sci USA* **106**: 18825–18830.

Veit G, Avramescu RG, Perdomo D, Phuan PW, Bagdany M, Apaja PM, Borot F, Szollosi D, Wu YS, and Finkbeiner WE et al. (2014) Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression. *Sci Transl Med* **6**:246ra97.

Veit G, Bossard F, Goepp J, Verkman AS, Galietta LJ, Hanrahan JW, and Lukacs GL (2012) Proinflammatory cytokine secretion is suppressed by TMEM16A or CFTR channel activity in human cystic fibrosis bronchial epithelia. *Mol Biol Cell* **23**:4188–4202.

Yamaya M, Finkbeiner WE, Chun SY, and Widdicombe JH (1992) Differentiated structure and function of cultures from human tracheal epithelium. *Am J Physiol* **262**:L713–L724.

Yang H, Shelat AA, Guy RK, Gopinath VS, Ma T, Du K, Lukacs GL, Taddei A, Folli C, and Pedemonte N et al. (2003) Nanomolar affinity small molecule correctors of defective Delta F508-CFTR chloride channel gating. *J Biol Chem* **278**:35079–35085.

**Address correspondence to:** Alan S. Verkman, 1246 Health Sciences East Tower, University of California, San Francisco, CA 94143-0521. E-mail: Alan.Verkman@ucsf.edu